Asia Pacific Laboratory Developed Tests Market To Reach $3.94 Billion By 2030

Asia Pacific Laboratory Developed Tests Market Growth & Trends

The Asia Pacific laboratory developed tests market size is anticipated to reach USD 3.94 billion by 2030 and is anticipated to grow at a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The region is witnessing a significant surge in cancer incidence, with an estimated 3.25 million new cases in China in 2024, 1 million new cases in Japan annually, and a projected 1.5 million cases in India by 2025. This trend has created a substantial demand for specialized diagnostic tests, driving the development of laboratory-developed tests (LDTs) tailored to specific patient needs and conditions.

China's implementation of Order 739 in 2021 has facilitated increased development of LDTs, while regulatory reforms in Japan, India, and Australia aim to streamline the approval process for diagnostics, including LDTs. Moreover, significant investments in laboratory automation technologies have enhanced efficiency and accuracy in testing procedures, making LDTs more appealing to healthcare providers.

The growing trend towards automation in laboratories has been pronounced in major hospitals in China and Japan, with adoption rates increasing by approximately 15% annually. Collaborative initiatives among academic institutions, research centers, and healthcare organizations in countries such as Japan and South Korea are driving innovation, enhancing the quality of diagnostic tests, and supporting market growth.

 Request a free sample copy or view report summary: Asia Pacific Laboratory Developed Tests Market Report

Asia Pacific Laboratory Developed Tests Market Report Highlights

• Based on technology, molecular diagnostics dominated the market with a revenue share of 20.0% in 2024, owing to its vital role in rapid pathogen detection and timely treatment decisions.

• Immunoassays are expected to grow at the fastest CAGR over the forecast period.

• Based on application, the oncology segment led the market in 2024, underscoring the need for advanced diagnostics such as LDTs. Innovations such as NGS and PCR have enhanced cancer diagnostics.

• Nutritional and metabolic diseases are projected to witness the fastest CAGR from 2025 and 2030. As aging populations in countries such as Japan and China are more vulnerable to these conditions, increasing the demand for specialized assessments.

• Based on region, China held the largest revenue share in the Asia Pacific laboratory-developed tests market in 2024, fueled by government initiatives and advancements in diagnostics, addressing the rising demand for personalized healthcare solutions for China’s aging population.

• In May 2024, Guardant Health secured EU IVDR certification for Guardant360 CDx in Europe, facilitating expanded genomic profiling of solid tumors and potentially prompting similar regulatory developments in Asia Pacific countries.

Asia Pacific Laboratory Developed Tests Market Segmentation

Grand View Research has segmented the Asia Pacific laboratory developed tests market based on technology, application, and country:

Asia Pacific Laboratory Developed Tests Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Immunoassays

• Hematology & Coagulation

• Molecular Diagnostics

• Microbiology

• Clinical Chemistry

• Histology/Cytology

• Flow Cytometry

• Mass Spectroscopy

• Others

Asia Pacific Laboratory Developed Tests Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

  • Companion Diagnostics

  • Genomics Sequencing and Others

• Genetic Disorders/Inherited Disease

• Infectious & Parasitic Diseases

• Immunology

• Endocrine

• Nutritional & Metabolic Diseases

• Cardiology

• Mental/Behavioral Disorder

• Pediatrics-Specific Testing

• Hematology/General Blood Testing

• Bodily Fluid Analysis

• Toxicology

• Others

Asia Pacific Laboratory Developed Tests Country Outlook (Revenue, USD Million, 2018 - 2030)

• Japan

• China

• India

• Thailand

• South Korea

• Australia

List of Key Players in Asia Pacific Laboratory Developed Tests (LDT) Market

• Quest Diagnostics Incorporated

• Abbott

• Guardant Health

• NeoGenomics Laboratories

• Siemens Healthcare Private Limited

• QIAGEN

• Illumina, Inc.

• F. Hoffmann-La Roche Ltd